Trial · NCT03863535
PRP vs PRP+IVC for Severe nPDR
NCT03863535, Not applicable, Unknown, Ruijin Hospital
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. PRP vs PRP+IVC for Severe nPDR. Trials, record NCT03863535. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03863535
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PRP vs PRP+IVC for Severe nPDR
- NCT number
- NCT03863535
- Status
- Unknown
- Phases
- Not applicable
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Ruijin Hospital
- Conditions
- Severe Nonproliferative Diabetic Retinopathy, Diabetic Retinopathy, Diabete Mellitus
- Interventions
- Conbercept, Panretinal coagulation
- First posted
- 2019-03-05
- Last updated
- 2019-03-05
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in best-corrected visual acuity (BCVA) | from baseline to month 12 | To assess the effects of two therapies on visual acuity |
| Secondary | Change in central subfield thickness | from baseline to month 12 | optical coherence tomography (OCT) for the assessment of central macular thickness |
| Secondary | Fundus fluorescein angiography | from baseline to month 12 | fluorescein angiography to measure area of fluorescein leakage (FLA) |
| Secondary | Foveal avascular zone | from baseline to month 12 | Optical coherence tomography angiography (OCTA) for measurement of FAZ |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03863535
GET https://conductscience.org/api/trials/v1/NCT03863535/registered